TY  - JOUR
PY  - 2005//
TI  - Risk of suicide and SSRIs
JO  - Connecticut medicine
A1  - Hanna, Nora
A1  - Karabelnik, Lisa
A1  - Ranga, Jyotsna
SP  - 541
EP  - 546
VL  - 69
IS  - 9
N2  - The controversy surrounding the use of Selective Serotonin Reuptake Inhibitors (SSRIs), in the treatment of depression and other psychiatric disorders in children and adolescents, has come to the forefront since the question of increased suicidal risk has been raised. There are limited research data available to thoroughly analyze the safety and efficacy of this class of medications in youths. In this article, we review the evidence available, the events that led to the black box warning, and the practical implications of the warning for providers, youth and families.
LA  - 
SN  - 0010-6178
UR  - http://dx.doi.org/
ID  - ref1
ER  -